Annemiek M.C. Gennissen

Author

Oncode Institute ORCID

Also Known As

A GENNISSEN, A M Gennissen, A. M. C. Gennissen, Annemiek Gennissen, Annemiek M. C. Gennissen, Annemiek M.C. Gennissen

Publications

764

Citations

H-Index

Concepts

All Affiliations

Oncode Institute The Netherlands Cancer Institute University Medical Center Groningen Iwate Medical University Charité - Universitätsmedizin Berlin

About

Annemiek M.C. Gennissen is an author at Oncode Institute specializing in medicine, pathology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	388
2	Cell Biology	2	2	388
3	Natural Sciences	1	1	373
4	Molecular Biology	1	1	373
5	Molecular Genetics	1	1	373

Annemiek M.C. Gennissen

Publications

753

Citations

H-Index

Page 1

	Year	Citations
Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. M J Ligtenberg, Hans L. Vos, Annemiek M.C. Gennissen, Journal of Biological Chemistry GeneticsGlycobiologyPathologyMolecular BiologyMolecular Genetics	1990	373
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors Katrien Berns, Joseph J. Caumanns, E. Marielle Hijmans, Oncogene	2018	113
A single nucleotide polymorphism in an exon dictates allele dependent differential splicing of episialin mRNA Marjolijn J. L. Ligtenberg, Annemiek M.C. Gennissen, Hans L. Vos, Nucleic Acids Research	1991	85
Isolation and expression of two novel <i>Wnt/wingless</i> gene homologues in <i>Drosophila</i> Jackie Russell, Annemiek M.C. Gennissen, Roel Nusse Development	1992	62
Loss of <i>ARID1A</i> Activates <i>ANXA1</i> , which Serves as a Predictive Biomarker for Trastuzumab Resistance Katrien Berns, Amir Sonnenblick, Annemiek M.C. Gennissen, Clinical Cancer Research	2016	55
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma Joseph J. Caumanns, Katrien Berns, G. Bea A. Wisman, Clinical Cancer Research	2018	50
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition Marta Llauradó Fernández, E. Marielle Hijmans, Annemiek M.C. Gennissen, Molecular Cancer Therapeutics Signaling PathwayMeki ResistanceEpithelial Ovarian CancerMedicineReceptor Tyrosine Kinase	2022	15

Page 1